Список литературы

1. Bessler M. et al. Paroxysmal nocturnal haemoglobinuria (PNH) is caused by somatic mutations in the PIG-A gene.//EMBO J. 1994. Vol. 13, N 1. P. 110 - 117.

2. Takeda J. et al. Deficiency of the GPI anchor caused by a somatic mutation of the PIG-A gene in paroxysmal nocturnal hemoglobinuria//Cell. 1993. Vol. 73, N 4. P. 703 - 711.

3. Medof B.Y.M.E., Kinoshita T., Nussenzweig V. INHIBITION OF COMPLEMENT OF CELLS AFTER ACTIVATION ON THE OF INCORPORATION (DAF) INTO THEIR MEMBRANES A key step in complement activation on targets is the deposition of C4b and/or C3b fragments. These major cleavage products of C3 and C4 can associa//Journal of Experimental Medicine. 1984. Vol. 160, N November. P. 1558 - 1578.

4. Lublin D.M., Atkinson J.P. Decay-Accelerating Factor: Biochemistry, Molecular Biology, and Function//Annu Rev Immunol. 1989. Vol. 7, N 1. P. 35 - 58.

5. Rollins S.A., Sims P.J. The complement-inhibitory activity of CD59 resides in its capacity to block incorporation of C9 into membrane C5b-9.//The Journal of Immunology. 1990. Vol. 144, N 9. P. 3478 LP - 3483.

6. Noris M., Remuzzi G. Overview of complement activation and regulation//Semin Nephrol. Elsevier, 2013. Vol. 33, N 6. P. 479 - 492.

7. Tegla C.A. et al. Membrane attack by complement: the assembly and biology of terminal complement complexes//Immunol Res. 2011. Vol. 51, N 1. P. 45 - 60.

8. Serna M. et al. Structural basis of complement membrane attack complex formation//Nat Commun. Nature Publishing Group, 2016. Vol. 7. P. 1 - 7.

9. Sun X. et al. Role of decay-accelerating factor in regulating complement activation on the erythrocyte surface as revealed by gene targeting//Proc Natl Acad Sci U S A. 1999. Vol. 96, N 2. P. 628 - 633.

10. Brodbeck W.G. et al. Structure/function studies of human decay-accelerating factor//Immunology. 2000. Vol. 101, N 1. P. 104 - 111.

11. Farkas I. et al. CD59 blocks not only the insertion of C9 into MAC but inhibits ion channel formation by homologous C5b-8 as well as C5b-9//J Physiol. 2002. Vol. 539, N 2. P. 537 - 545.

12. Bessler M., Hiken J. The pathophysiology of disease in patients with paroxysmal nocturnal hemoglobinuria.//Hematology/the Education Program of the American Society of Hematology. American Society of Hematology. Education Program. 2008. P. 104 - 110.

13. Hill A., Kelly R.J., Hillmen P. Thrombosis in paroxysmal nocturnal hemoglobinuria//Blood. 2013. Vol. 121, N 25. P. 4985 - 4996.

14. Rother R.P. et al. The Clinical Sequelae of Intravascular Hemolysis and Extracellular Plasma Hemoglobin//JAMA. 2005. Vol. 293, N 13. P. 1653.

15. Olsen S.B. et al. Enhancement of Platelet Deposition by Cross-Linked Hemoglobin in a Rat Carotid Endarterectomy Model//Circulation. 1996. Vol. 93, N 2. P. 327 - 332.

16. Simionatto C.S. et al. Thrombophlebitis and disturbed hemostasis following administration of intravenous hematin in normal volunteers//Am J Med. 1988. Vol. 85, N 4. P. 538 - 540.

17. Studt J.-D. et al. Fatal congenital thrombotic thrombocytopenic purpura with apparent ADAMTS13 inhibitor: in vitro inhibition of ADAMTS13 activity by hemoglobin//Blood. 2005. Vol. 105, N 2. P. 542 - 544.

18. Seregina E.A. et al. Eculizumab effect on the hemostatic state in patients with paroxysmal nocturnal hemoglobinuria//Blood Cells Mol Dis. 2015. Vol. 54, N 2. P. 144 - 150.

19. Ritis K. et al. A Novel C5a Receptor-Tissue Factor Cross-Talk in Neutrophils Links Innate Immunity to Coagulation Pathways//The Journal of Immunology. 2006. Vol. 177, N 7. P. 4794 - 4802.

20. Wojta J. et al. C5a stimulates production of plasminogen activator inhibitor-1 in human mast cells and basophils//Blood. 2002. Vol. 100, N 2. P. 517 - 523.

21. Yu F., Du Y., Han B. A comparative analysis of clinical characteristics of patients with paroxysmal nocturnal hemoglobinuria between Asia and Europe/America//Int J Hematol. Springer Japan, 2016. Vol. 103, N 6. P. 649 - 654.

22. Hill A. et al. Paroxysmal nocturnal haemoglobinuria//Nat Rev Dis Primers. 2017. Vol. 3, N 1. P. 17028.

23. Hill A. et al. The incidence and prevalence of paroxysmal nocturnal hemoglobinuria (PNH) and survival of patients in Yorkshire.//Blood. 2006. Vol. 108, N September 2018. P. Abstract 985.

24. Кулагин А.Д. et al. Клиническая манифестация и ошибки диагностики классической пароксизмальной ночной гемоглобинурии: анализ 150 наблюдений//Клиническая онкогематология. 2017. Vol. 10, N 3. P. 333 - 341.

25. Hillmen P. et al. Long-term effect of the complement inhibitor eculizumab on kidney function in patients with paroxysmal nocturnal hemoglobinuria//Am J Hematol. 2010. Vol. 85, N 8. P. 553 - 559.

26. Hill A. et al. Under-recognized complications in patients with paroxysmal nocturnal haemoglobinuria: Raised pulmonary pressure and reduced right ventricular function//Br J Haematol. 2012. Vol. 158, N 3. P. 409 - 414.

27. Sahin F. et al. Pesg PNH diagnosis, follow-up and treatment guidelines. 2016. Vol. 6, N 2. P. 19 - 27.

28. Brodsky R.A. Paroxysmal nocturnal hemoglobinuria//Blood. 2014. Vol. 124, N 18. P. 2804 - 2811.

29. Кулагин А.Д. et al. Национальные клинические рекомендации по диагностике и лечению пароксизмальной ночной гемоглобинурии//Онкогематология. 2014. Vol. 2. P. 20 - 28.

30. Borowitz M.J. et al. Guidelines for the diagnosis and monitoring of paroxysmal nocturnal hemoglobinuria and related disorders by flow cytometry//Cytometry B Clin Cytom. Wiley-Liss Inc., 2010. Vol. 78, N 4. P. 211 - 230.

31. Manivannan P., Ahuja A., Pati H.P. Diagnosis of Paroxysmal Nocturnal Hemoglobinuria: Recent Advances//Indian Journal of Hematology and Blood Transfusion. Springer India, 2017. Vol. 33, N 4. P. 453 - 462.

32. Movalia M.K. et al. Incidence of PNH Clones by Diagnostic Code Utilizing High Sensitivity Flow Cytometry//Blood. 2011. Vol. 118, N 21. P. 1033 - 1033.

33. Sipol A.A. et al. An inter-laboratory comparison of PNH clone detection by high-sensitivity flow cytometry in a Russian cohort//Hematology. 2015. Vol. 20, N 1. P. 31 - 38.

34. Dezern A.E., Borowitz M.J. ICCS/ESCCA consensus guidelines to detect GPI-deficient cells in paroxysmal nocturnal hemoglobinuria (PNH) and related disorders part 1 - clinical utility//Cytometry B Clin Cytom. 2018. Vol. 94, N 1. P. 16 - 22.

35. Sutherland D.R. et al. ICCS/ESCCA consensus guidelines to detect GPI-deficient cells in paroxysmal nocturnal hemoglobinuria (PNH) and related disorders part 2 - reagent selection and assay optimization for high-sensitivity testing//Cytometry B Clin Cytom. 2018. Vol. 94, N 1. P. 23 - 48.

36. Brubaker L.H., Essig L.R.J., Mengel C.E. Neutrophil life span in paroxysmal nocturnal hemoglobinuria//Blood. 1977. Vol. 50, N 4. P. 657 - 662.

37. Patriquin C.J. et al. How we treat paroxysmal nocturnal hemoglobinuria: A consensus statement of the Canadian PNH Network and review of the national registry//European Journal of Haematology. Blackwell Publishing Ltd, 2019. Vol. 102, N 1. P. 36 - 52.

38. Бокерия Л.А., Затевахин И.И., Кириенко А.И. Российские клинические рекомендации по диагностике, лечению и профилактике венозных тромбоэмболических осложнений (ВТЭО).//Флебология. 2015. Vol. 4, N 2. P. 3 - 52.

39. Villegas A. et al. Spanish consensus statement for diagnosis and treatment of paroxysmal nocturnal haemoglobinuria//Med Clin (Barc). Ediciones Doyma, S.L., 2016. Vol. 146, N 6. P. 278e1 - 278e7.

40. Hill A. et al. Sustained response and long-term safety of eculizumab in paroxysmal nocturnal hemoglobinuria//Blood. 2005. Vol. 106, N 7. P. 2559 - 2565.

41. Hillmen P. et al. The Complement Inhibitor Eculizumab in Paroxysmal Nocturnal Hemoglobinuria//New England Journal of Medicine. 2006. Vol. 355, N 12. P. 1233 - 1243.

42. Savva S. The Potential of a Museum-School Partnership to Support Diversity and Multiliteracies-Based Pedagogy for the 21st Century. 2016. Vol. 111, N 4. P. 1840 - 1848.

43. Hillmen P. et al. Effect of Eculizumab on Hemolysis and Transfusion Requirements in Patients with Paroxysmal Nocturnal Hemoglobinuria//New England Journal of Medicine. 2004. Vol. 350, N 6. P. 552 - 559.

44. Reiss U.M. et al. Efficacy and safety of eculizumab in children and adolescents with paroxysmal nocturnal hemoglobinuria//Pediatr Blood Cancer. Pediatr Blood Cancer, 2014. Vol. 61, N 9. P. 1544 - 1550.

45. Lee J.W. et al. Ravulizumab (ALXN1210) vs eculizumab in adult patients with PNH naive to complement inhibitors: the 301 study//Blood. 2019. Vol. 133, N 6. P. 530 - 539.

46. Kulasekararaj A.G. et al. Ravulizumab (ALXN1210) vs eculizumab in C5-inhibitor-experienced adult patients with PNH: the 302 study//Blood. 2019. Vol. 133, N 6. P. 540 - 549.

47. McNamara L.A. et al. High Risk for Invasive Meningococcal Disease Among Patients Receiving Eculizumab (Soliris) Despite Receipt of Meningococcal Vaccine//MMWR Morb Mortal Wkly Rep. 2017. Vol. 66, N 27. P. 734 - 737.

48. Brodsky R.A. et al. Characterization of breakthrough hemolysis events observed in the phase 3 randomized studies of ravulizumab versus eculizumab in adults with paroxysmal nocturnal hemoglobinuria//Haematologica. 2020. Vol. 106, N 1. P. 230 - 237.

49. Инструкция по медицинскому применению препарата пэгцетакоплан ЛП-N(002459)-(РГ-RU) от 02.06.2023. Государственный реестр лекарственных средств.

50. Debureaux P.-E. et al. Categorizing hematological response to eculizumab in paroxysmal nocturnal hemoglobinuria: a multicenter real-life study//Bone Marrow Transplant. 2021. Vol. 56, N 10. P. 2600 - 2602.

51. Brodsky R.A. Stem cell transplantation for paroxysmal nocturnal hemoglobinuria. 2010. Vol. 95, N 6. P. 855 - 856.

52. de Latour R.P. et al. Allogeneic stem cell transplantation in paroxysmal nocturnal hemoglobinuria//Haematologica. 2012. Vol. 97, N 11. P. 1666 - 1673.

53. SHASHELEVA D.A. et al. Hematopoietic stem cell transplantation with alpha/beta T-lymphocyte depletion and short course of eculizumab in adolescents and young adults with paroxysmal nocturnal hemoglobinuria//Ter Arkh. 2018. Vol. 90, N 7. P. 57 - 64.

54. Young N.S. et al. The Management of Paroxysmal Nocturnal Hemoglobinuria: Recent Advances in Diagnosis and Treatment and New Hope for Patients//Semin Hematol. W.B. Saunders, 2009. Vol. 46, N SUPPL. 1.

55. Brecher M., Taswell H. Paroxysmal nocturnal hemoglobinuria and the transfusion of washed red cells. A myth revisited//Transfusion (Paris). 1989. Vol. 29, N 8. P. 681 - 685.

56. Parker C. Diagnosis and management of paroxysmal nocturnal hemoglobinuria//Blood. 2005. Vol. 106, N 12. P. 3699 - 3709.

57. R.D. et al. Consensus statement for diagnosis and treatment of paroxysmal nocturnal haemoglobinuria//Hematol Transfus Cell Ther. 2021. Vol. 43, N 3. P. 341 - 348.

58. Kulasekararaj A.G., Brodsky R.A., Hill A. Monitoring of patients with paroxysmal nocturnal hemoglobinuria on a complement inhibitor//Am J Hematol. 2021. Vol. 96, N 7.

59. Ayuk F., Balduzzi A. Donor Selection for Adults and Pediatrics//The EBMT Handbook: Hematopoietic Stem Cell Transplantation and Cellular Therapies/ed. Carreras E. et al. Springer, 2019. P. 87 - 99.

60. Carreras E., Rambaldi A. Evaluation and Counseling of Candidates//EBMT Handbook: Hematopoietic Stem Cell Transplantation and Cellular Therapies. 7th ed./ed. Carreras E. et al. Springer, 2019. P. 77 - 87.

61. Confer D.L., Miller J.P., Chell J.W. Bone Marrow and Peripheral Blood Cell Donors and Donor Registries//Thomas' Hematopoietic Cell Transplantation. Chichester, UK: John Wiley & Sons, Ltd, 2016. Vol. 1 - 2. P. 423 - 432.

62. Witt V., Peters C. Collection of HSC in Children//The EBMT Handbook: Hematopoietic Stem Cell Transplantation and Cellular Therapies. 7th ed./ed. Carreras E. et al. Springer, 2019. P. 123 - 127.

63. Gorin N.C. Bone Marrow Harvesting for HSCT//The EBMT Handbook: Hematopoietic Stem Cell Transplantation and Cellular Therapies. 7th ed./ed. Carreras E. et al. Springer, 2019. P. 109 - 117.

64. Gorin N.C. Bone Marrow Harvesting for HSCT//The EBMT Handbook: Hematopoietic Stem Cell Transplantation and Cellular Therapies. 7th ed./ed. Carreras E. et al. Springer, 2019. P. 109 - 117.

65. K. Mobilization and Collection of HSC//The EBMT Handbook: Hematopoietic Stem Cell Transplantation and Cellular Therapies. 7th ed./ed. Carreras E. et al. Springer, 2019. P. 117 - 123.

66. Querol S., Rocha V. Procurement and Management of Cord Blood//The EBMT Handbook: Hematopoietic Stem Cell Transplantation and Cellular Therapies. 7th ed./ed. Carreras E. et al. Springer, 2019. P. 131 - 137.

67. Wuchter P. Processing, Cryopreserving and Controlling the Quality of HSCs//The EBMT Handbook: Hematopoietic Stem Cell Transplantation and Cellular Therapies. 7th ed./ed. Carreras E. et al. Springer, 2019. P. 127 - 131.

68. Schumm M., Lang P., Handgretinger R. Graft Manipulation//The EBMT Handbook: Hematopoietic Stem Cell Transplantation and Cellular Therapies. 7th ed./ed. Carreras E. et al. Springer, 2019. P. 137 - 143.

69. Nagler A., Shimoni A. Conditioning//The EBMT Handbook: Hematopoietic Stem Cell Transplantation and Cellular Therapies. 7th ed./ed. Carreras E. et al. Springer, 2019. P. 99 - 109.

70. Danylesko I., Shimoni A., Nagler A. Treosulfan-based conditioning before hematopoietic SCT: more than a BU look-alike//Bone Marrow Transplantation 2012 47:1. Nature Publishing Group, 2011. Vol. 47, N 1. P. 5 - 14.

71. Ruutu T. How to use busulfan in conditioning for allogeneic transplantation//Cell Ther Transplant. Universitatsklinikum Hamburg - Eppendorf, 2018. Vol. 7, N 1. P. 18 - 20.

72. Langenhorst J.B. et al. Population Pharmacokinetics of Fludarabine in Children and Adults during Conditioning Prior to Allogeneic Hematopoietic Cell Transplantation//Clin Pharmacokinet. Springer, 2019. Vol. 58, N 5. P. 627.

73. Yoshida N. et al. Conditioning regimen for allogeneic bone marrow transplantation in children with acquired bone marrow failure: fludarabine/melphalan vs. fludarabine/cyclophosphamide//Bone Marrow Transplantation 2020 55:7. Nature Publishing Group, 2020. Vol. 55, N 7. P. 1272 - 1281.

74. Penack O. et al. Prophylaxis and management of graft versus host disease after stem-cell transplantation for haematological malignancies: updated consensus recommendations of the European Society for Blood and Marrow Transplantation//The Lancet Haematology. Elsevier Ltd, 2020. Vol. 7, N 2. P. e157 - e167.

75. Michonneau D., G. GVHD Prophylaxis (Immunosuppression)//The EBMT Handbook: Hematopoietic Stem Cell Transplantation and Cellular Therapies. 7th ed./ed. Carreras E. et al. Springer, 2019. P. 177 - 183.

76. Michonneau D., G. GVHD Prophylaxis (Immunosuppression)//The EBMT Handbook: Hematopoietic Stem Cell Transplantation and Cellular Therapies. 7th ed./ed. Carreras E. et al. Springer, 2019. P. 177 - 183.

77. Watanabe N. et al. Relationship between tacrolimus blood concentrations and clinical outcome during the first 4 weeks after SCT in children//Bone Marrow Transplantation 2010 45:7. Nature Publishing Group, 2009. Vol. 45, N 7. P. 1161 - 1166.

78. Jacoby E. et al. Single agent post-transplantation cyclophosphamide as GVHD prophylaxis after HLA-matched related BMT for pediatric and young adult patients with hematologic malignancies//Biol Blood Marrow Transplant. NIH Public Access, 2016. Vol. 22, N 1. P. 112.

79. Baron F. et al. Anti-thymocyte globulin as graft-versus-host disease prevention in the setting of allogeneic peripheral blood stem cell transplantation: a review from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation//Haematologica. 2017. Vol. 102, N 2.

80. Koreth J. et al. Bortezomib-based immunosuppression after reduced-intensity conditioning hematopoietic stem cell transplantation: randomized phase II results//Haematologica. Ferrata Storti Foundation, 2018. Vol. 103, N 3. P. 522 - 530.

81. Wertheimer T. et al. Abatacept as salvage therapy in chronic graft-versus-host disease - a retrospective analysis//Ann Hematol. 2021. Vol. 100, N 3. P. 779 - 787.

82. Drobyski W.R. et al. Tocilizumab for the Treatment of Steroid Refractory Graft-versus-Host Disease//Biology of Blood and Marrow Transplantation. Elsevier, 2011. Vol. 17, N 12. P. 1862 - 1868.

83. Abouelnasr A. et al. Defining the Role of Sirolimus in the Management of Graft-versus-Host Disease: From Prophylaxis to Treatment//Biology of Blood and Marrow Transplantation. 2013. Vol. 19. P. 12 - 21.

84. H. et al. A prospective single-center study on CNI-free GVHD prophylaxis with everolimus plus mycophenolate mofetil in allogeneic HCT//Annals of Hematology 2021 100:8. Springer, 2021. Vol. 100, N 8. P. 2095 - 2103.

85. Malard F. et al. Rituximab-based first-line treatment of cGVHD after allogeneic SCT: results of a phase 2 study//Blood. Content Repository Only!, 2017. Vol. 130, N 20. P. 2186 - 2195.

86. Cutler C., Antin J.H. Manifestations and Treatment of Acute Graft-versus-Host Disease//Thomas' Hematopoietic Cell Transplantation. Chichester, UK: John Wiley & Sons, Ltd, 2016. Vol. 2 - 2. P. 1012 - 1025.

87. Holler E., Greinix H., Zeiser R. Acute Graft-Versus-Host Disease//The EBMT Handbook: Hematopoietic Stem Cell Transplantation and Cellular Therapies. 7th ed./ed. Carreras E. et al. Springer, 2019. P. 323 - 330.

88. Toubai T., Magenau J. Immunopathology and biology-based treatment of steroid-refractory graft-versus-host disease//Blood. American Society of Hematology, 2020. Vol. 136, N 4. P. 429 - 440.

89. Martin P.J. How I treat steroid-refractory acute graft-versus-host disease//Blood. American Society of Hematology, 2020. Vol. 135, N 19. P. 1630 - 1638.

90. Nassar A. et al. Methotrexate for the Treatment of Graft-versus-Host Disease after Allogeneic Hematopoietic Stem Cell Transplantation//J Transplant. Hindawi Limited, 2014. Vol. 2014. P. 1 - 10.

91. Kawashima N. et al. Prophylaxis and treatment with mycophenolate mofetil in children with graft-versus-host disease undergoing allogeneic hematopoietic stem cell transplantation: a nationwide survey in Japan//International Journal of Hematology 2019 109:4. Springer, 2019. Vol. 109, N 4. P. 491 - 498.

92. Khandelwal P. et al. The successful use of alemtuzumab for treatment of steroid-refractory acute graft-versus-host disease in pediatric patients//Pediatr Transplant. Pediatr Transplant, 2014. Vol. 18, N 1. P. 94 - 102.

93. Vicent M.G. et al. Ruxolitinib treatment for steroid refractory acute and chronic graft vs host disease in children: Clinical and immunological results//Am J Hematol. John Wiley & Sons, Ltd, 2019. Vol. 94, N 3. P. 319 - 326.

94. Faraci M. et al. Etanercept as Treatment of Steroid-Refractory Acute Graft-versus-Host Disease in Pediatric Patients//Biology of Blood and Marrow Transplantation. Elsevier, 2019. Vol. 25, N 4. P. 743 - 748.

95. Sleight B.S. et al. Infliximab for GVHD therapy in children//Bone Marrow Transplantation 2007 40:5. Nature Publishing Group, 2007. Vol. 40, N 5. P. 473 - 480.

96. Albert M.H. et al. Oral graft vs. host disease in children - Treatment with topical tacrolimus ointment//Pediatr Transplant. Pediatr Transplant, 2007. Vol. 11, N 3. P. 306 - 309.

97. Zangrilli A. et al. Treatment of disfiguring chronic graft versus host disease in a child with topical pimecrolimus//Pediatrics International. Pediatr Int, 2010. Vol. 52, N 3. P. e161 - 3.

98. Baird K. et al. Imatinib Mesylate for the Treatment of Steroid-Refractory Sclerotic-Type Cutaneous Chronic Graft-versus-Host Disease//Biology of Blood and Marrow Transplantation. Biol Blood Marrow Transplant, 2015. Vol. 21, N 6. P. 1083 - 1090.

99. Wolff D., Lawitschka A. Chronic Graft-Versus-Host Disease//The EBMT Handbook: Hematopoietic Stem Cell Transplantation and Cellular Therapies. 7th ed./ed. Carreras E. et al. Springer, 2019. P. 331 - 347.

100. Filipovich A.H. et al. National Institutes of Health Consensus Development Project on criteria for clinical trials in chronic graft-versus-host disease: I. diagnosis and staging working group report//Biology of Blood and Marrow Transplantation. Biol Blood Marrow Transplant, 2005. Vol. 11, N 12. P. 945 - 956.

101. Jagasia M.H. et al. National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group Report//Biology of Blood and Marrow Transplantation. Elsevier Inc., 2015. Vol. 21, N 3. P. 389 - 401. e1.

102. Mikulska M. Infection Control and Isolation Procedures//The EBMT Handbook: Hematopoietic Stem Cell Transplantation and Cellular Therapies. 7th ed./ed. Carreras E. et al. Springer, 2019. P. 189 - 197.

103. Mikulska M. Neutropenic Fever//The EBMT Handbook: Hematopoietic Stem Cell Transplantation and Cellular Therapies. 7th ed./ed. Carreras E. et al. Springer, 2019. P. 259 - 265.

104. Ljungman P., Styczynski J., Einsele H. Viral Infections//The EBMT Handbook: Hematopoietic Stem Cell Transplantation and Cellular Therapies. 7th ed./ed. Carreras E. et al. Springer, 2019. P. 281 - 291.

105. Maertens J.A. Invasive Fungal Infections//The EBMT Handbook: Hematopoietic Stem Cell Transplantation and Cellular Therapies. 7th ed./ed. Carreras E. et al. Springer, 2019. P. 273 - 281.

106. Groll A.H. et al. Fourth European Conference on Infections in Leukaemia (ECIL-4): Guidelines for diagnosis, prevention, and treatment of invasive fungal diseases in paediatric patients with cancer or allogeneic haemopoietic stem-cell transplantation//The Lancet Oncology. Lancet Publishing Group, 2014. Vol. 15, N 8.

107. Cesaro S. Haemorrhagic Cystitis and Renal Dysfunction//The EBMT Handbook: Hematopoietic Stem Cell Transplantation and Cellular Therapies. 7th ed./ed. Carreras E. et al. Springer, 2019. P. 387 - 393.

108. Carreras E., Diaz-Ricart M. Early Complications of Endothelial Origin//EBMT Handbook: Hematopoietic Stem Cell Transplantation and Cellular Therapies. 7th ed./ed. Carreras E. et al. Springer, 2019. P. 315 - 323.

109. Mahadeo K.M. et al. Diagnosis, grading, and treatment recommendations for children, adolescents, and young adults with sinusoidal obstructive syndrome: an international expert position statement//The Lancet Haematology. Elsevier Ltd, 2020. Vol. 7, N 1. P. e61 - e72.

110. Sung L. et al. Guideline for the prevention of oral and oropharyngeal mucositis in children receiving treatment for cancer or undergoing haematopoietic stem cell transplantation//BMJ Supportive and Palliative Care. BMJ Publishing Group, 2017. Vol. 7, N 1. P. 7 - 16.

111. Ghali M.G.Z. et al. Posterior reversible encephalopathy syndrome in pediatric patients: pathophysiology, diagnosis, and management//Leukemia and Lymphoma. Taylor and Francis Ltd, 2019. Vol. 60, N 10. P. 2365 - 2372.

112. Cooke K.R. Acute lung injury after allogeneic stem cell transplantation: From the clinic, to the bench and back again//Pediatr Transplant. John Wiley & Sons, Ltd, 2005. Vol. 9, N SUPPL. 7. P. 25 - 36.

113. Jodele S. et al. New approaches in the diagnosis, pathophysiology, and treatment of pediatric hematopoietic stem cell transplantation-associated thrombotic microangiopathy//Transfusion and Apheresis Science. Elsevier Ltd, 2016. Vol. 54, N 2. P. 181 - 190.

114. Baumgartner A., Schuetz P. Nutritional Support//The EBMT Handbook: Hematopoietic Stem Cell Transplantation and Cellular Therapies. 7th ed./ed. Carreras E. et al. Springer, 2019. P. 171 - 177.

115. Schrezenmeier H. et al. Transfusion Support//The EBMT Handbook: Hematopoietic Stem Cell Transplantation and Cellular Therapies. 7th ed./ed. Carreras E. et al. Springer, 2019. P. 163 - 171.

116. Bahar B., Tormey C.A. Prevention of transfusion-associated graft-versus-host disease with blood product irradiation the past, present, and future//Archives of Pathology and Laboratory Medicine. College of American Pathologists, 2018. Vol. 142, N 5. P. 662 - 667.